Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Moodys
Medtronic
Harvard Business School
Merck

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEPAKENE

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Depakene

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00382590 Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients Completed M.D. Anderson Cancer Center Phase 2 2005-08-01 Primary Objective: 1. To evaluate whether 5 azacytidine (5-aza)/valproic acid (VPA) or low dose ara-C produces longer event free survival time in patients age > or = 60 years with untreated Acute Myeloid Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS) who are typically ineligible for, or not placed on, studies of new agents. Secondary Objective: 1. To evaluate whether pre-treatment methylation/acetylation status in AML/MDS blasts predicts response to either therapy or whether the ability of the 5 azacytidine + valproic acid combination to induce demethylation or acetylation parallels response.
NCT00513162 Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases Completed M.D. Anderson Cancer Center Phase 1 2007-07-01 Primary Objective: - Determine the interindividual range and median of individual maximum tolerated doses of valproic acid administered as one time evening dose in conjunction with a dose oral etoposide (50 mg/m2/day for children, but only 25mg/m2/day for adults to start) for four different age groups. Secondary Objectives: - Determine the qualitative and quantitative toxicity and reversibility of toxicity of valproic acid in conjunction with oral etoposide, - To investigate the clinical pharmacokinetics of valproic acid when given in conjunction with oral etoposide, - To describe quality of life of patients with relapsed, or progressive central and peripheral nervous system tumors when treated with oral valproic acid and etoposide, - To observe and describe the response pattern of progressive central nervous system tumors treated with oral valproic acid and etoposide, - To observe and describe event free survival time and overall survival time of patients with relapsed, or progressive central nervous system tumors when treated with oral valproic acid and etoposide, - To determine if histone deacetylase activity and topoisomerase expression in lymphocytes of patients is related to valproic acid levels, and - To determine, if the individual maximal tolerated dose (iMTD) depends on the initial performance status of the patient in the beginning of the treatment.
NCT01272531 Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD) Unknown status University of California, San Diego Phase 4 2011-01-01 This is a prospective pharmacogenomics study of mood stabilizer response. The goal of this work is to identify genes associated with good response of patients with bipolar disorder to two commonly used mood stabilizing agents, lithium and valproate.
NCT01750541 Haloperidol vs. Valproate in Agitation Completed Shahid Beheshti University of Medical Sciences Phase 3 2012-12-01 The aim of this study is to compare the efficacy of haloperidol and valproate in management of people with agitation in emergency department
NCT01900730 Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter Recruiting Inflammatory Breast Cancer Network Foundation Phase 2 2014-08-01 The goal of this clinical research study is to learn if receiving valproic acid (VPA) compared to a placebo can reduce the amount of time you will need to have an indwelling pleural catheter compared to the standard of care, which involves using an indwelling pleural catheter alone. VPA is designed to stop cancer cells from dividing and maturing. This may cause the cancer cells to become less malignant and cause less pleural fluid production. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
NCT01900730 Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter Recruiting M.D. Anderson Cancer Center Phase 2 2014-08-01 The goal of this clinical research study is to learn if receiving valproic acid (VPA) compared to a placebo can reduce the amount of time you will need to have an indwelling pleural catheter compared to the standard of care, which involves using an indwelling pleural catheter alone. VPA is designed to stop cancer cells from dividing and maturing. This may cause the cancer cells to become less malignant and cause less pleural fluid production. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Depakene

Condition Name

Condition Name for Depakene
Intervention Trials
Breast Cancer 1
Brain Metastases 1
Psychomotor Agitation 1
Bipolar Affective Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Depakene
Intervention Trials
Disease 1
Syndrome 1
Bipolar Disorder 1
Preleukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Depakene

Trials by Country

Trials by Country for Depakene
Location Trials
United States 12
Canada 1
Norway 1
Iran, Islamic Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Depakene
Location Trials
Texas 3
Kentucky 1
Pennsylvania 1
Ohio 1
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Depakene

Clinical Trial Phase

Clinical Trial Phase for Depakene
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Depakene
Clinical Trial Phase Trials
Completed 3
Recruiting 2
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Depakene

Sponsor Name

Sponsor Name for Depakene
Sponsor Trials
M.D. Anderson Cancer Center 3
Kimberly S Jones 1
Inflammatory Breast Cancer Network Foundation 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Depakene
Sponsor Trials
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Dow
Harvard Business School
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.